Compare · ABBV vs CYRX
ABBV vs CYRX
Side-by-side comparison of AbbVie Inc. (ABBV) and CryoPort Inc. (CYRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and CYRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $464.58B, about 553.6x CYRX ($839.3M).
- Over the past year, ABBV is up 23.8% and CYRX is up 88.8% - CYRX leads by 65.0 points.
- ABBV has been more active in the news (18 items in the past 4 weeks vs 5 for CYRX).
- Both have 25 recent analyst ratings on file.
- Company
- AbbVie Inc.
- CryoPort Inc.
- Price
- $257.88-1.91%
- $16.57-0.57%
- Market cap
- $464.58B
- $839.3M
- 1M return
- -2.27%
- +9.23%
- 1Y return
- +23.82%
- +88.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 18
- 5
- Recent ratings
- 25
- 25
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
CryoPort Inc.
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities are maintained throughout the shipping cycle; and Cryoport Express Advanced Therapy Shippers that provides verification processes to biopharma companies. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
Latest ABBV
- AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
- AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
- EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas sold $8,177,500 worth of shares (32,710 units at $250.00) and exercised 32,710 shares at a strike of $79.02 (SEC Form 4)
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
- AbbVie upgraded by Wolfe Research with a new price target
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices
- SEC Form 424B5 filed by AbbVie Inc.
Latest CYRX
- Amendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.
- President, CEO Shelton Jerrell sold $429,385 worth of shares (28,800 units at $14.91) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,201,814 units (SEC Form 4)
- SEC Form 10-Q filed by CryoPort Inc.
- CryoPort Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cryoport Reports Second Quarter 2026 Financial Results
- Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026
- Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
- SEC Form S-8 filed by CryoPort Inc.
- SEC Form 15-12G filed by CryoPort Inc.
- Chief Digital and Tech Officer Zecchini Edward J exercised 35,000 shares at a strike of $4.80 and sold $507,563 worth of shares (35,000 units at $14.50) (SEC Form 4)